Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | ACHE | P22303 | 2/20 | 0.38 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | HTR2B | P41595 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL17965629 | 0.98 | HTR2C (0.38) | HTR2CACHENQO2MTNR1AMTNR1B | |
| SCHEMBL18033567 | 0.84 | DRD2 (0.35) | HTR2CHTR2BDRD2 | |
| SCHEMBL17965649 | 0.79 | HTR2A (0.40) | HTR2CHTR2BDRD2 | |
| SCHEMBL4243156 | 0.78 | ACHE (0.46) | ACHENQO2MTNR1AMTNR1BKDM4E | |
| SCHEMBL29507238 | 0.71 | HTR2C (0.36) | HTR2CHTR2B | |
| SCHEMBL21326101 | 0.71 | SLC6A4 (0.36) | HTR2CHTR2BKDM4ELMNASLC6A4 | |
| SCHEMBL21326102 | 0.71 | HTR2A (0.31) | HTR2CHTR2B | |
| SCHEMBL22858964 | 0.71 | HTR2C (0.36) | HTR2CHTR2B | |
| SCHEMBL29587253 | 0.71 | HTR2A (0.31) | HTR2CHTR2B | |
| SCHEMBL18034949 | 0.71 | ALDH1A1 (0.41) | ACHENQO2MTNR1AMTNR1BDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015050212-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | 日産化学工業株式会社 | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | HTR2C 1102/4885ACHE 2037/4885NQO2 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.